Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.51 |
| ▸ | KLK7 | P49862 | 3/20 | 0.47 |
| ▸ | LTA4H | P09960 | 6/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1375011 | 1.00 | S1PR1 (0.51) | S1PR1KLK7LTA4HSCN9AFNTA | |
| SCHEMBL1371550 | 0.94 | KLK7 (0.52) | S1PR1KLK7LTA4HSLC1A3SLC1A2 | |
| SCHEMBL1371555 | 0.94 | KLK7 (0.52) | S1PR1KLK7LTA4HSLC1A3SLC1A2 | |
| SCHEMBL1373783 | 0.94 | S1PR1 (0.47) | S1PR1KLK7LTA4HSCN9AFNTA | |
| SCHEMBL1373786 | 0.94 | S1PR1 (0.47) | S1PR1KLK7LTA4HSCN9AFNTA | |
| SCHEMBL1371620 | 0.94 | S1PR1 (0.58) | S1PR1LTA4HFNTAFNTBSLC1A3 | |
| SCHEMBL1371622 | 0.94 | S1PR1 (0.58) | S1PR1LTA4HFNTAFNTBSLC1A3 | |
| Trifluoroacetic Acid SCHEMBL1372090 | 0.89 | S1PR1 (0.54) | S1PR1LTA4HFNTAFNTBSLC1A3 | |
| SCHEMBL1372073 | 0.86 | S1PR1 (0.62) | S1PR1LTA4H | |
| SCHEMBL1372071 | 0.86 | S1PR1 (0.62) | S1PR1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885KLK7 2551/4885LTA4H 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.